Editorial: anti‐tumour necrosis factor α antibodies – can efficacy be regained?

Bar-Yoseph, Haggai; Chowers, Yehuda

doi:10.1111/apt.14047

Aliment Pharmacol Ther

2017

DOI: 10.1111/apt.14047

|View full text |Cite

Editorial: anti‐tumour necrosis factor α antibodies – can efficacy be regained?

Haggai Bar-Yoseph

Yehuda Chowers

Abstract: 3. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017; 389:266-275.4. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Loss of response to anti-tumour necrosis factor antibodies (anti-TNF) agents remains a difficult problem in the treatment of inflammatory bowel disease (IBD). The goal of our retrospective analysis was to investigate how many patients at our centre with secondary loss of response due to immunogenicity received an immunomodulator in an attempt to regain clinical response.…”

mentioning

confidence: 99%